Literature DB >> 622047

Abnormal concentration and anomalous distribution of apolipoprotein A-I in Tangier disease.

L O Henderson, P N Herbert, D S Fredrickson, R J Heinen, J C Easterling.   

Abstract

A double-antibody radioimmunoassay was used to determine the concentration and distribution of apolipoprotein A-I (apoA-I) in the plasma of patients with Tangier disease. Obligate heterozygotes for Tangier disease had apoA-I levels that were 50% or less of controls, even when estimates of high-density lipoprotein cholesterol concentration were normal. Plasma apoA-I levels in Tangier homozygotes were at most 3% of normal. Most of the apoA-I in the plasma of homozygotes sedimented in the ultracentrifuge at density 1.21 g/ml, and no more than 20% was recovered in the plasma lipoprotein fraction. Radioimmunoassay demonstrated no immunochemical differences between Tangier and control apoA-I.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 622047     DOI: 10.1016/0026-0495(78)90162-2

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  3 in total

1.  Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes.

Authors:  S M Clee; J J Kastelein; M van Dam; M Marcil; K Roomp; K Y Zwarts; J A Collins; R Roelants; N Tamasawa; T Stulc; T Suda; R Ceska; B Boucher; C Rondeau; C DeSouich; A Brooks-Wilson; H O Molhuizen; J Frohlich; J Genest; M R Hayden
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

2.  Apolipoprotein B-100 deficiency. Intestinal steatosis despite apolipoprotein B-48 synthesis.

Authors:  P N Herbert; J S Hyams; D N Bernier; M M Berman; A L Saritelli; K M Lynch; A V Nichols; T M Forte
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

3.  Tangier disease. High density lipoprotein deficiency due to defective metabolism of an abnormal apolipoprotein A-i (ApoA-ITangier).

Authors:  E J Schaefer; L L Kay; L A Zech; H B Brewer
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.